bioAffinity Technologies, Inc. (BIAF): Nasdaq/NYSE listing notice — bioAffinity receives Nasdaq delisting notice; equity of $1.44M below $2.5M minimum

bioAffinity Technologies, Inc.

Stockholders' equity was $1,439,404 as of March 31, 2025, well below the $2,500,000 minimum.
Company must submit a compliance plan by July 11, 2025 (45 days) to regain compliance.
If plan accepted, Nasdaq may grant up to 180-day extension from May 27, 2025.
Trading continues on Nasdaq Capital Market under BIAF and BIAFW symbols pending resolution.
This notice is separate from prior bid price deficiency notice received February 7, 2025.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 27, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $1,439,404 as of March 31, 2025, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, was below the minimum requirement of $2,500,000. As of the date of this Current Report on Form 8-K, the Company does not have a market value of listed secu

View on SEC.gov

3 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-013021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.